Tg Therapeutics (TGTX) Asset Writedowns and Impairment (2013)

Tg Therapeutics (TGTX) recorded quarterly Asset Writedowns and Impairment of $2.8 million in Q4 2013.

Tg Therapeutics (TGTX) Asset Writedowns and Impairment (2013) Analysis & Trends

Tg Therapeutics' Asset Writedowns and Impairment history runs 1 years deep, the most recent figure standing at $2.8 million for Q4 2013.

In Q4 2013, Asset Writedowns and Impairment changed N/A year-over-year to $2.8 million; the TTM figure through Mar 2014 stood at $2.8 million (changed N/A YoY), while the FY2025 annual figure was $6.2 million, changed N/A from the prior year.
Asset Writedowns and Impairment was $2.8 million for Q4 2013 at Tg Therapeutics.
In the past five years, Asset Writedowns and Impairment ranged from a high of $2.8 million in Q4 2013 to a low of $2.8 million in Q4 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Tg Therapeutics	7.71 Bn	7.06 Bn	171.41 Mn

Download Data

Date	Value
Dec 31, 2013	2.80 Mn
Dec 31, 2013	2.80 Mn